Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company advancing ...
A fatal, highly hereditary illness with no disease-modifying treatments, Huntington’s is long overdue for a therapeutic win.
The past four years have brought disappointment for the Huntington’s community, but optimism is growing as companies ...
Johnson & Johnson seeks US & EU approvals for Darzalex Faspro/Darzalex as subcutaneous monotherapy for high-risk smoldering multiple myeloma: Raritan, New Jersey Monday, November ...
Neurizon has been buoyed by the receipt of a positive opinion from the European Medicines Agency in relation to its ...
While the final decision is set for next month, biotech player Neurizon’s (ASX:NUZ) hopes have been lifted with a view ...
The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...
Raritan: Johnson & Johnson has announced the submission of regulatory applications to the U.S. Food and Drug Administration ...
New medicines, access to treatments, infectious disease monitoring, and more are on the table.View on euronews ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback